NewAmsterdam Pharma Company NVNASDAQ:NAMS
- LAST PRICE18.8600
- TODAY'S CHANGE (%)0.1400 (0.7479%)
- Bid / Lots20.5000/ 1
- Ask / Lots22.8000/ 2
- Open / Previous Close18.7500 / 18.7200
- Day Range
- 52 Week Range
- Volume87,419
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NAMS |
|---|---|---|
| 09:32 ET | 798 | 18.75 |
| 09:36 ET | 100 | 18.74 |
| 09:38 ET | 275 | 18.9639 |
| 09:43 ET | 100 | 18.845 |
| 09:56 ET | 100 | 18.84 |
| 10:03 ET | 5551 | 18.92 |
| 10:10 ET | 100 | 18.7 |
| 10:12 ET | 402 | 18.81 |
| 10:32 ET | 100 | 18.81 |
| 10:33 ET | 229 | 18.81 |
| 10:35 ET | 633 | 18.81 |
| 10:39 ET | 662 | 18.83 |
| 10:48 ET | 100 | 18.805 |
| 10:50 ET | 200 | 18.8574 |
| 11:04 ET | 300 | 18.89 |
| 11:06 ET | 800 | 18.9 |
| 11:08 ET | 1100 | 18.895 |
| 11:29 ET | 800 | 18.78 |
| 11:40 ET | 100 | 18.845 |
| 12:00 ET | 1300 | 18.855 |
| 12:02 ET | 300 | 18.795 |
| 12:05 ET | 6000 | 18.875 |
| 12:27 ET | 1600 | 18.8 |
| 12:34 ET | 100 | 18.81 |
| 12:36 ET | 2700 | 18.81 |
| 12:41 ET | 607 | 18.885 |
| 12:50 ET | 629 | 18.805 |
| 12:52 ET | 100 | 18.805 |
| 01:08 ET | 100 | 18.825 |
| 01:21 ET | 100 | 18.835 |
| 01:32 ET | 200 | 18.875 |
| 01:35 ET | 400 | 18.82 |
| 01:37 ET | 200 | 18.8 |
| 01:39 ET | 400 | 18.795 |
| 01:46 ET | 100 | 18.795 |
| 01:50 ET | 600 | 18.795 |
| 01:53 ET | 200 | 18.79 |
| 02:08 ET | 1500 | 18.85 |
| 02:45 ET | 169 | 18.8078 |
| 03:02 ET | 400 | 18.81 |
| 03:09 ET | 1694 | 18.77 |
| 03:12 ET | 100 | 18.87 |
| 03:18 ET | 100 | 18.77 |
| 03:39 ET | 100 | 18.88 |
| 03:41 ET | 902 | 18.9 |
| 03:43 ET | 200 | 18.9 |
| 03:45 ET | 800 | 18.89 |
| 03:48 ET | 7311 | 18.89 |
| 03:50 ET | 400 | 18.9 |
| 03:52 ET | 400 | 18.905 |
| 03:54 ET | 100 | 18.88 |
| 03:56 ET | 1076 | 18.92 |
| 03:57 ET | 312 | 18.91 |
| 03:59 ET | 1510 | 18.86 |
Today
Jul 18, 2024
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors, from 8:00AM ET on Thursday Jul 18, 2024 by Dow Jones
8:00AM ET on Thursday Jul 18, 2024 by Dow JonesPress Release: NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors, from 8:00AM ET on Thursday Jul 18, 2024 by Dow Jones
8:00AM ET on Thursday Jul 18, 2024 by Dow Jones
Jul 8, 2024
Jul 3, 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:01PM ET on Wednesday Jul 03, 2024 by Dow Jones
4:01PM ET on Wednesday Jul 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NewAmsterdam Pharma Company NV | 1.7B | -7.0x | --- |
Soleno Therapeutics Inc | 1.6B | -18.1x | --- |
Edgewise Therapeutics Inc | 1.7B | -12.4x | --- |
Kura Oncology Inc | 1.6B | -9.7x | --- |
Verona Pharma PLC | 1.8B | -28.7x | --- |
Keros Therapeutics Inc | 1.8B | -10.2x | --- |
Company Information
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Contact Information
- Headquarters
- Gooimeer 2-35NAARDEN, Netherlands 1411 DC
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- William Lewis
- Chief Executive Officer, Executive Director
- Michael Davidson
- Interim Chief Financial Officer
- Louise Kooij
- Chief Operating Officer
- Douglas Kling
- Chief Scientific Officer, Non-Executive Director
- John Kastelein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.7B |
|---|---|
Revenue (TTM) | $6.9M |
Shares Outstanding | 90.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.02 |
EPS | $-2.70 |
Book Value | $3.50 |
P/E Ratio | -7.0x |
Price/Sales (TTM) | 245.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,894.14% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
